Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Enanta Pharmaceuticals (ENTA)
NASDAQ:ENTA
RESEARCH TOOLSreports
Holding ENTA?
Track your performance easily
ENTA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.08 - $17.80
Previous Close$11.39
Volume63.95K
Average Volume (3M)165.25K
Market Cap
$243.24M
Enterprise Value$61.82M
Total Cash (Recent Filing)$230.09M
Total Debt (Recent Filing)$50.57M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Nov 25, 2024EPS Estimate
-$1.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.46
Shares Outstanding21,188,571
10 Day Avg. Volume116,223
30 Day Avg. Volume165,247
Standard Deviation0.16
R-Squared0.04
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.62
Price to Sales (P/S)3.43
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.85
Enterprise Value/Gross Profit0.78
Enterprise Value/Ebitda-0.51
Forecast
1Y Price Target
$20.43Price Target Upside77.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Enanta Pharmaceuticals News
PremiumPre-Earnings
Is ENTA a Buy, Before Earnings?
PremiumCompany Announcements
Enanta Pharmaceuticals Shareholders Affirm Management DirectionBulls Say, Bears Say
Bulls Say
Financial PerformanceEnanta ended the quarter with cash of ~$300M and guided to runway through F3Q27.
Immunology ProgramEnanta expects to select a clinical candidate from its new immunology program for chronic spontaneous urticaria (CSU), targeting a primary driver of CSU.
RSV Clinical TrialsCompletion of enrollment for the RSVPEDs Phase 2 study is seen as a crucial milestone, particularly because the pediatric population represents a key high-risk RSV group.
Bears Say
Clinical TrialsThere is skepticism around the RSVHR program given the previous Phase 2 trial failure in otherwise healthy adults.
Financial PerformanceEnanta reported fiscal 2Q24 results with total royalty revenues of ~$17M for Mavyret in HCV which were ~3% below the estimate.
Research And DevelopmentRSVPEDs has had a shift in timing for data to 2H24, vs. a prior 3Q, due to slower-than-expected enrollment.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ENTA FAQ
What was Enanta Pharmaceuticals’s price range in the past 12 months?
Enanta Pharmaceuticals lowest stock price was $8.08 and its highest was $17.80 in the past 12 months.
What is Enanta Pharmaceuticals’s market cap?
Currently, no data Available
When is Enanta Pharmaceuticals’s upcoming earnings report date?
Enanta Pharmaceuticals’s upcoming earnings report date is Nov 25, 2024 which is in 66 days.
How were Enanta Pharmaceuticals’s earnings last quarter?
Enanta Pharmaceuticals released its earnings results on Aug 05, 2024. The company reported -$1.07 earnings per share for the quarter, beating the consensus estimate of -$1.432 by $0.362.
Is Enanta Pharmaceuticals overvalued?
According to Wall Street analysts Enanta Pharmaceuticals’s price is currently Undervalued.
Does Enanta Pharmaceuticals pay dividends?
Enanta Pharmaceuticals does not currently pay dividends.
What is Enanta Pharmaceuticals’s EPS estimate?
Enanta Pharmaceuticals’s EPS estimate is -$1.16.
How many shares outstanding does Enanta Pharmaceuticals have?
Enanta Pharmaceuticals has 21,188,572 shares outstanding.
What happened to Enanta Pharmaceuticals’s price movement after its last earnings report?
Enanta Pharmaceuticals reported an EPS of -$1.07 in its last earnings report, beating expectations of -$1.432. Following the earnings report the stock price went up 1.167%.
Which hedge fund is a major shareholder of Enanta Pharmaceuticals?
Among the largest hedge funds holding Enanta Pharmaceuticals’s share is Farallon Capital Management, L.L.C.. It holds Enanta Pharmaceuticals’s shares valued at 27M.
---
Enanta Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.81%
12-Months-Change
Fundamentals
Return on Equity
-59.64%
Trailing 12-Months
Asset Growth
-19.46%
Trailing 12-Months
Company Description
Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
---
ENTA Company Deck
---
ENTA Earnings Call
Q2 2024
0:00 / 0:00
---
ENTA Stock 12 Month Forecast
Average Price Target
$20.43
▲(77.96% Upside)
Technical Analysis
Best Analysts Covering ENTA
1 Year
1 Year Success Rate
8/18 ratings generated profit
1 Year Average Return
+7.06%
assigned a buy rating 2 months ago
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +7.06% per trade.
---